ascopubs.org

Enfortumab vedotin (EV) as monotherapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of stage I of a phase 2 trial.

Radiographic progression without PSA progression in metastatic hormone-sensitive prostate cancer (mHSPC): A retrospective analysis from the ENZAMET trial (ANZUP 1304). This is an ASCO Meeting Abstract ...
ascopubs.org

Treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC): A systematic literature review of 35 real-world observational studies.

Evaluation of time to metastasis (TTM) from prostatectomy and survival in patients (pts) with metachronous metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen deprivation therapy ...
Cure Today

Castration ‘An Unfortunate Term’ for Key Part of Prostate Cancer Treatment

An expert explains the necessity of managing patients’ testosterone levels while treating prostate cancer. When treating patients with prostate cancer, controlling testosterone levels in the body is ...
Cure Today

FDA Approves Nubeqa in Metastatic Castration-Sensitive Prostate Cancer

Nubeqa (darolutamide) received FDA approval for metastatic castration-sensitive prostate cancer, showing significant improvement in radiographic progression-free survival. The ARANOTE trial involved ...